TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02159066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: Combination of LGX818 and MEK162 (Part I)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Combination of LGX818 and MEK162 (Part I)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: Combination of LGX818 + MEK162 + LEE011 (Part II)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: Combination of LGX818 + MEK162 + BGJ398 (Part II)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Combination of LGX818 + MEK162 + BKM120 (Part II)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: Combination of LGX818 + MEK162 + INC280 (Part II)
Study: NCT01949935

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mupirocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Study: NCT02022137

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red cereal bar
Description: Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Green cereal bar
Description: Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White cereal bar
Description: Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
Study: NCT03431298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise & movement control
Description: The aerobic exercise content is no different between the experimental group and the active comparator group.~The movement control is individual training which divided into fourths progressing sessions.~* First, lumbo-pelvic and hip dynamic direction control.~* Second, trunk muscle groups, hip muscle groups and thigh muscle groups extensibility control.~* Third, trunk muscle groups and hip muscle groups through range control.~* Fourth, functional movement control training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: The aerobic exercise will organized in groups. Each group has 6-8 persons. The exercise form is fixed at each time.~The description of exercise form is as below:~* 10 min Warm up~* 40 min Aerobic exercise (which focus on lower extremity muscle strengthening and increasing muscle endurance)~* 10 min Cool down
Study: NCT03881839

Intervention type: OTHER
Intervention: emergency
Description: The objective of this research will be to assess, in patients presenting in an emergency department, the prior consultation of medical information on a website, the impact on the emergency consultation decision and the relevance of this consultation.
Study: NCT04066868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes assessment
Description: Patient-reported outcomes are electronically assessed using EORTC QOL measures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-reported outcomes assessment
Description: Patient-reported outcomes are electronically assessed using EORTC QOL measures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTCAE rating
Description: CTCAE Ratings are conducted by clinicians

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CTCAE rating
Description: CTCAE Ratings are conducted by clinicians

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRO data is displayed
Description: PRO data is displayed right next to the CTCAE rating
Study: NCT04291846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459 fasted in P1, high-fat diet in P2
Description: SHR1459 administration in fasted condition in period 1, SHR1459 administration after high-fat diet in period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459 high-fat diet in P1, fasted in P2
Description: SHR1459 administration after high-fat diet in period 1, SHR1459 administration in fasted condition in period 2
Study: NCT03495830

Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: Exploration of carotid bifurcation. Clamping of carotid artery and plaque removal with endarterectomy. Plaque is stored. Suture of artery with direct suture or patch.

Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: Exploration of carotid bifurcation. Clamping of carotid artery and plaque removal with endarterectomy. Plaque is stored. Suture of artery with direct suture or patch.
Study: NCT04958824

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic test
Description: Pharmacogenetic test results for Cytochrome P450 genes are examined for markers of variant metabolism.
Study: NCT01620060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 20, 40,80, 120 or 160 mg/day oral single and multiple does of lurasidone for 12 days
Study: NCT05239052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer task intervention
Description: subject received programs for upper arm movement training with providing computer screen task activities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional long-term care services
Description: stroke subjects with wheelchair users receive conventional long-term care services
Study: NCT02609308

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short leg cast
Description: Immobilization with short leg cast with a dorsiflexed foot for two weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament
Study: NCT03438617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer leaders. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer leaders will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer leaders and participants.
Study: NCT00115440

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Bononophenylalanine (BPA)-based BNCT
Description: Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
Study: NCT02004730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABSORB implantation
Description: ABSORB implantation for long (\> 24mm) single vessel disease

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABSORB implantation
Description: ABSORB implantation for long (\> 24mm) single vessel disease

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABSORB implantation
Description: ABSORB implantation for long (\> 24mm) single vessel disease
Study: NCT03663829

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT00628121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 1, 2 or 3mg, subcutaneouly dosed with single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 1, 2 or 3mg, subcutaneouly dosed with single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 1, 2 or 3mg, subcutaneouly dosed with single dose
Study: NCT01950858

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Weight reduction

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight reduction
Study: NCT00890734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT003-QbG10
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection
Study: NCT00648336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine 50 mg
Description: 50mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purinethol® Tablets 50 mg
Description: 50mg, single dose fasting
Study: NCT00923520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMS 612
Description: DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
Study: NCT01022736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Subjects will be administered gabapentin (600 mg, orally) 1 hour prior to cardiac bypass surgery, 1 hour following extubation, then every 8 hours for a total of 4 doses.
Study: NCT04664153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 ointment
Description: PF-07038124 ointment at 0.01% with QD dosing for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 ointment
Description: PF-07038124 ointment at 0.01% with QD dosing for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment
Description: Vehicle ointment with QD dosing for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle ointment
Description: Vehicle ointment with QD dosing for 6 weeks
Study: NCT03383926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4.5cm suture
Description: Suture confection of the Tobacco-pouch of 4.5cm from the anal margin.
Study: NCT03964103

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gQ-lab daily
Description: probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: powdered skim milk, lactose
Study: NCT00252421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin ointment 15 mg/day daily for 24 month
Description: Nitroglycerin ointment 15 mg/day applied daily for 24 mth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment daily for 24 month
Description: Placebo ointment applied daily for 24 mth
Study: NCT01692184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg AVL-292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg AVL-292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg AVL-292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350 mg AVL-292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study: NCT00189098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfamethoxazole-trimethoprim
Description: 18 mg/kg, two times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04404179

Intervention type: OTHER
Intervention: COVID-19 FACILITY
Description: A COVID-19 facility was setup within the Prison. All positive prisoners were managed in the facility. If further intervention was required they were to be shifted to Services Hospital , Lahore.
Study: NCT02399215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04575506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program
Description: The intervention program includes an educational program promoting healthy dietary habits and physical activity (nutritionist and exercise physiologist) (2 times/month, for children and parents), and supervised home-based exercise (from 3 to 5 times/week, 38-44 min) program for 12-weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary intervention program
Description: The intervention program includes an educational program promoting healthy dietary habits and physical activity (nutritionist and exercise physiologist) (2 times/month, for children and parents), and supervised home-based exercise (from 3 to 5 times/week, 38-44 min) program for 12-weeks.
Study: NCT02843724

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Naturopathic Care
Description: Naturopathic diabetes care will be selected from a pre-approved menu. Participants' other health concerns will be addressed at naturopathic doctors' discretion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual (Conventional) Care
Description: 2016 Canadian Diabetes Clinical Practice Guidelines (self-management, blood-glucose-lowering, vascular protection, pharmacotherapy) will be implemented

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual (Conventional) Care
Description: 2016 Canadian Diabetes Clinical Practice Guidelines (self-management, blood-glucose-lowering, vascular protection, pharmacotherapy) will be implemented
Study: NCT02268149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01172106

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: drug compliance
Description: Mothers and their caregivers will be encouraged to comply with the given medication

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Encouragement of drug compliance
Description: Mothers and their caregivers in the placebo comparator will receive an intervention of drug compliance encouragement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family psychoeducation
Description: The experimental group will receive family psychoeducation for 12 sessions
Study: NCT00716963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate (Flovent Diskus) 250 mcg
Description: Flovent Diskus 250 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide 400 mcg
Description: budesonide 400 mcg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03497663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIA Family intervention
Description: Family based intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Treatment As Usual
Study: NCT00450970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Satraplatin
Description: The SPERA protocol states that satraplatin may be continued until evidence of disease progression (at the discretion of the investigator), intolerable toxicity, withdrawal of informed consent, or non compliance. The treatment consists of satraplatin 80 mg/m2 administered by mouth once daily for five consecutive days (days 1-5) plus prednison 5 mg po twice daily. The treatment cycle is repeated every 35 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Satraplatin
Description: The SPERA protocol states that satraplatin may be continued until evidence of disease progression (at the discretion of the investigator), intolerable toxicity, withdrawal of informed consent, or non compliance. The treatment consists of satraplatin 80 mg/m2 administered by mouth once daily for five consecutive days (days 1-5) plus prednison 5 mg po twice daily. The treatment cycle is repeated every 35 days.
Study: NCT03305666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine injection
Description: A single injection of liposomal bupivacaine is administered at the time of SSRF, directly to the fracture site via VATS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine indwelling catheter
Description: Bupivacaine indwelling OnQ pain pump catheter is placed in the subscapular space at the time of SSRF for continuous bupivacaine infusion post op
Study: NCT02745171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: Will be held 15 sessions, 2 times a week, lasting 50 minutes, a physical therapy protocol developed by the Pro-Parkinson Physiotherapy based on the Guide of the Dutch Society of Physiotherapy (Keus, 2004).
Study: NCT01022021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Day 1 - rituximab, 375 mg/M2 IV (drug dosage is based on body weight)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Days 2 and 3 bendamustine, 90 mg/M2 IV over 30-60 minutes (drug dosage based on body weight)
Study: NCT02334930

Intervention type: OTHER
Intervention: Biopsy
Study: NCT02542865

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified malt based food
Description: Fortified malt based food
Study: NCT02677298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection, sodium chloride 0.9 mg divided in five 0.1mL i.m. injections into glabellar area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area in up to 3 treatment cycles
Study: NCT04629755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention was delivered via daily text messages to mobile phones during two weeks in the midst of the Covid-19 pandemic. Each message provided a link to a brief suggestion for an action or actions to take each day to improve relational closeness and well-being. Critical to the rationale for this intervention was the position that relationship science has developed key insights into what works and does not work to build and maintain closeness. These insights could be translated into brief and effective suggestions that individuals could implement daily, thereby quickly improving relational well-being and decreasing depression and loneliness at a critical time.
Study: NCT02360566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory Video Intervention for Early Psychosis
Description: The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
Study: NCT00947375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamictal TM
Description: First group patients received either haloperidol deaconate 50 mg in weekly intramuscular and Lamictal TM 150-200 mg in day per so for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol Decanoate
Description: Second group patients were given haloperidol deaconate 50 mg in weekly intramuscular and placebo per os for 12 weeks.
Study: NCT02503592

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular testing
Description: Patients who have received a cochlear implant within 90 days, and had vestibular testing pre-operatively, will undergo post-op vestibular testing
Study: NCT01099371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: progressive resistance training
Study: NCT02229058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Bound Paclitaxel
Description: 120 mg/m2, D1,D8,every 3 weeks until disease progress or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 40mg QD D1-D14,every 3 weeks,for BSA\<1.25 m2, 50mg QD D1-D14,every 3 weeks,for BSA=1.25～1.5m2, 60mg QD D1-D14,every 3 weeks,for BSA\>1.5m2,until disease progress or intolerable toxicity.
Study: NCT03707353

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 ME-TRAP and MVA ME-TRAP vaccination
Description: vaccination with ChAd63 ME-TRAP 5x10\^10 vp (intramuscularly and intravenously) vaccination with MVA METRAP 2x10\^8 pfu (intramuscularly) and MVA METRAP 2x10\^7 pfu (intravenously) Group 5 will be challenged with malaria by mosquito bite.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 ME-TRAP and MVA ME-TRAP vaccination
Description: vaccination with ChAd63 ME-TRAP 5x10\^10 vp (intramuscularly and intravenously) vaccination with MVA METRAP 2x10\^8 pfu (intramuscularly) and MVA METRAP 2x10\^7 pfu (intravenously) Group 5 will be challenged with malaria by mosquito bite.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 ME-TRAP and MVA ME-TRAP vaccination
Description: vaccination with ChAd63 ME-TRAP 5x10\^10 vp (intramuscularly and intravenously) vaccination with MVA METRAP 2x10\^8 pfu (intramuscularly) and MVA METRAP 2x10\^7 pfu (intravenously) Group 5 will be challenged with malaria by mosquito bite.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 ME-TRAP and MVA ME-TRAP vaccination
Description: vaccination with ChAd63 ME-TRAP 5x10\^10 vp (intramuscularly and intravenously) vaccination with MVA METRAP 2x10\^8 pfu (intramuscularly) and MVA METRAP 2x10\^7 pfu (intravenously) Group 5 will be challenged with malaria by mosquito bite.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 ME-TRAP and MVA ME-TRAP vaccination
Description: vaccination with ChAd63 ME-TRAP 5x10\^10 vp (intramuscularly and intravenously) vaccination with MVA METRAP 2x10\^8 pfu (intramuscularly) and MVA METRAP 2x10\^7 pfu (intravenously) Group 5 will be challenged with malaria by mosquito bite.